Liu Shuanshuan, Ruan Yanyun, Chen Xu, He Bao, Chen Qi
Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Front Cell Dev Biol. 2024 Aug 23;12:1427724. doi: 10.3389/fcell.2024.1427724. eCollection 2024.
Lung cancer is a prevalent malignancy and the leading cause of cancer-related deaths, posing a significant threat to human health. Despite advancements in treatment, the prognosis for lung cancer patients remains poor due to late diagnosis, cancer recurrence, and drug resistance. Epigenetic research, particularly in microRNAs, has introduced a new avenue for cancer prevention and treatment. MicroRNAs, including miR-137, play a vital role in tumor development by regulating various cellular processes. MiR-137 has garnered attention for its tumor-suppressive properties, with studies showing its potential in inhibiting cancer progression. In lung cancer, miR-137 is of particular interest, with numerous reports exploring its role and mechanisms. A comprehensive review is necessary to consolidate current evidence. This review highlights recent studies on miR-137 in lung cancer, covering cell proliferation, migration, apoptosis, drug resistance, and therapy, emphasizing its potential as a biomarker and therapeutic target for lung cancer treatment and prognosis.
肺癌是一种常见的恶性肿瘤，也是癌症相关死亡的主要原因，对人类健康构成重大威胁。尽管治疗取得了进展，但由于诊断延迟、癌症复发和耐药性，肺癌患者的预后仍然很差。表观遗传学研究，特别是在微小RNA方面，为癌症的预防和治疗开辟了一条新途径。微小RNA，包括miR-137，通过调节各种细胞过程在肿瘤发展中发挥重要作用。MiR-137因其肿瘤抑制特性而受到关注，研究表明其在抑制癌症进展方面具有潜力。在肺癌中，miR-137特别受关注，有许多报道探讨了它的作用和机制。有必要进行全面综述以巩固现有证据。本综述重点介绍了近期关于miR-137在肺癌中的研究，涵盖细胞增殖、迁移、凋亡、耐药性和治疗，强调其作为肺癌治疗和预后的生物标志物及治疗靶点的潜力。
